Jeanne Fringer

FDA investigator · also recorded as Ssee Jeanne Fringer

Appears on 6 documents from 2021 to 2025, most often at sites in California. Most often cites general requirements (21 CFR 211.160).

6
Documents on file
6.4
Observations per 483
2021
First seen
2025
Most recent

What they cite most

From 40 observations

Activity by year

2021: 1, 2022: 2, 2023: 1, 2024: 1, 2025: 1

Where

California 1 · China 1 · France 1 · India 1 · Maryland 1 · South Korea 1

Is Jeanne Fringer coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

6 documents, newest first
FirmOpen
483 Bio-Thera Solutions, LtdJan 17, 2025 · Huangpu Di strict, China
483 STgen Bio Co., Ltd.Jun 25, 2024 · Incheon, South Korea
483 Intas Pharmaceuticals LimitedDec 7, 2023 · Ahmedabad, India
483 Merck BiodevelopmentOct 14, 2022 · Martillac, France
483 Genentech, Inc.May 26, 2022 · South San Francisco, California
483 MacroGenics, IncApr 6, 2021 · Rockville, Maryland

About this profile

What does Jeanne Fringer inspect?

Jeanne Fringer appears on 6 documents on file covering 6 sites, most often in California.

What do they cite most often?

21 CFR 211.160 (general requirements), followed by 21 CFR 211.113 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Jeanne Fringer is dated Jan 17, 2025.